From the Journals

CD49d trumps novel recurrent mutations for predicting overall survival in CLL


 

CD49d was a strong predictor of overall survival in a cohort of 778 unselected patients with chronic lymphocytic leukemia, reported Michele Dal Bo, MD, of Centro di Riferimento Oncologico, in Aviano, Italy, and colleagues.

©Ed Uthman/Flickr
The finding held true even when patients were placed into subgroups on the basis of mutations or deletions of the TP53, NOTCH1, SF3B1 and BIRC3 genes, the researchers noted (Leukemia 2016 Oct;30[10]:2011-18).

High CD49d expression was an independent predictor of poor overall survival in a multivariate Cox analysis (hazard ratio = 1.88, P less than .0001) and in each category of a risk stratification model. Among other biological prognosticators, CD49d was among the top predictors of overall survival (variable importance = 0.0410) along with immunoglobulin heavy chain variable (IGHV) gene mutational status and TP53 abnormalities. “In this context, TP53 disruption and NOTCH1 mutations retained prognostic relevance, in keeping with their roles in CLL cell immuno-chemoresistance,” the authors wrote.

Recommended Reading

CAR T-cell start-up launched
MDedge Hematology and Oncology
Venetoclax achieves responses in CLL refractory to ibrutinib, idelalisib
MDedge Hematology and Oncology
Dr. Matt Kalaycio’s top 10 hematologic oncology abstracts for ASCO 2016
MDedge Hematology and Oncology
Maintenance rituximab extends progression-free but not overall survival in CLL
MDedge Hematology and Oncology
Ibrutinib at below standard dose may achieve good survival in CLL
MDedge Hematology and Oncology
Acalabrutinib shows efficacy as monotherapy in untreated CLL
MDedge Hematology and Oncology
Three-drug regimen boosts progression-free survival in patients with relapsed CLL and adverse prognostic features
MDedge Hematology and Oncology
CAR T-cell therapy eyed for CLL patients with residual disease
MDedge Hematology and Oncology
CLL: Genetic aberrations predict poor treatment response in elderly
MDedge Hematology and Oncology
Survival in CLL predicted by minimum residual disease
MDedge Hematology and Oncology